Education
About Us
Working with TipRanks
Follow Us
Devonian Health Group, Inc. (TSE:GSD)
:GSD
GSD Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.35
Previous CloseN/A
VolumeN/A
Average Volume (3M)973.00
Market Cap
C$23.72M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)2.18M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Jun 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding148,222,530
10 Day Avg. Volume2,919
30 Day Avg. Volume973
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Devonian Health Group News
PremiumCompany Announcements
Devonian Health Group Resumes Trading on TSXV
PremiumCompany Announcements
Devonian Health Group Reports Strong Q2 Revenue Growth and Strategic Advances
PremiumCompany Announcements
Devonian Health Group Faces Cease Trade Order Amid Filing Delays
PremiumCompany Announcements
Devonian Health Group Delays Financial Reporting Due to Restatement Needs
PremiumCompany Announcements
Devonian Health Group Announces Key Approvals at Annual Shareholder MeetingPremiumCompany Announcements
Devonian Health Group Files Patent for Thykamine™ as Antifibrotic Agent
PremiumCompany Announcements
Devonian Health Group Files Patent for Thykamine™ in Liver Disease TreatmentGSD FAQ
What was Devonian Health Group, Inc.’s price range in the past 12 months?
Devonian Health Group, Inc. lowest stock price was C$0.07 and its highest was C$0.35 in the past 12 months.
What is Devonian Health Group, Inc.’s market cap?
Devonian Health Group, Inc.’s market cap is C$23.72M.
When is Devonian Health Group, Inc.’s upcoming earnings report date?
Devonian Health Group, Inc.’s upcoming earnings report date is Jun 25, 2025 which is in 31 days.
How were Devonian Health Group, Inc.’s earnings last quarter?
Devonian Health Group, Inc. released its earnings results on Apr 15, 2025. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.002.
Is Devonian Health Group, Inc. overvalued?
According to Wall Street analysts Devonian Health Group, Inc.’s price is currently Overvalued.
Does Devonian Health Group, Inc. pay dividends?
Devonian Health Group, Inc. does not currently pay dividends.
What is Devonian Health Group, Inc.’s EPS estimate?
Devonian Health Group, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Devonian Health Group, Inc. have?
Devonian Health Group, Inc. has 148,222,530 shares outstanding.
What happened to Devonian Health Group, Inc.’s price movement after its last earnings report?
Devonian Health Group, Inc. reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Devonian Health Group, Inc.?
Currently, no hedge funds are holding shares in TSE:GSD
Company Description
Devonian Health Group, Inc.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It is intended to develop prescription botanical drugs which could be from plant materials, algae, macroscopic fungi, and combinations thereof. The company's technology platform, The Supra Molecular Complex Extraction, and Stabilization Technology provide a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. The products of the group include botanical pharmaceuticals, Thykamine; and derma-cosmeceutical product, Purgenesis.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BriaCell Therapeutics
―
Sirona Biochem
―
PharmaTher Holdings Ltd
―
Thiogenesis Therapeutics Corp
―